Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model

Muscle and Nerve

Volumn 48, Issue 2, 2013, Pages 279-285

  Miciak, Jessica J ^a   Warsing, Leigh C ^a   Tibbs, Maria E ^a   Jasper, Jeffrey R ^b   Jampel, Sarah B ^a   Malik, Fady I ^b   Tankersley, Clarke ^c   Wagner, Kathryn R ^a,c  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b Cytokinetics Inc   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dy2J; Muscular dystrophy; Preclinical; Tirasemtiv; Troponin complex

Indexed keywords

CARBON DIOXIDE; CREATINE KINASE; LAMININ ALPHA2; PLACEBO; TIRASEMTIV; TROPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM; DRUG MEGADOSE; FOREARM; GRIP STRENGTH; MOUSE; MUSCLE CELL; MUSCLE EXERCISE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RESPIRATORY FUNCTION; SKELETAL MUSCLE; TRICEPS BRACHII MUSCLE;

DY2J; MUSCULAR DYSTROPHY; PRECLINICAL; TIRASEMTIV; TROPONIN COMPLEX;

ANALYSIS OF VARIANCE; ANIMALS; CREATINE KINASE; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; LAMININ; LONGITUDINAL STUDIES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCULAR DYSTROPHIES; MUTATION; PHYSICAL ENDURANCE; PYRAZINES; RESPIRATORY PHYSIOLOGICAL PHENOMENA; TROPONIN;

EID: 84881024264     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23848     Document Type: Article

References (33)

1. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, et al. Mutations in the laminin [alpha]2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995;11:216-218.
2. Allamand V, Sunada Y, Salih MAM, Straub V, Ozo O, Al-Turaiki MHS, et al. Mild congenital muscular dystrophy in two patients with an internally deleted laminin alpha2-chain. Hum Mol Genet 1997;6:747-752.
3. Matsumura K, Yamada H, Saito F, Sunada Y, Shimizu T. Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Neuromuscul Disord 1997;7:7-12.
4. Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet 2002;10:91-94.
5. Di Muzio A, De Angelis MV, Di Fulvio P, Ratti A, Pizzuti A, Stuppia L, et al. Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve 2003;27:500-506.
6. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal. Neuromuscul Disord 1995;5:301-305.
7. Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, et al. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord 2010;20:241-250.
8. Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 2001;38:649-657.
9. Miyagoe-Suzuki Y, Nakagawa M, Takeda SI. Merosin and congenital muscular dystrophy. Microsc Res Tech 2000;48:181-191.
10. Michelson AM, Russell ES, Harman PJ. Dystrophia muscularis: a hereditary primary myopathy in the house mouse. Proc Natl Acad Sci 1955;41:1079-1084.
11. Xu H, Wu X-R, Wewer UM, Engvall E. Murine muscular dystrophy caused by a mutation in the laminin [alpha]2 (Lama2) gene. Nat Genet 1994;8:297-302.
12. Sunada Y. Identification of a novel mutatnt transcript of laminin a2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum Mol Genet 1995;4:1055-1061.
13. Colognato H, Yurchenco PD. The laminin α2 expressed by dystrophic dy2J mice is defective in its ability to form polymers. Curr Biol 1999;9:1327-1330.
14. Dadush O, Aga-Mizrachi S, Ettinger K, Tabakman R, Elbaz M, Fellig Y, et al. Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate. Neuromuscul Disord 2010;20:267-272.
15. Nevo Y, Aga-Mizrachi S, Elmakayes E, Yanay N, Ettinger K, Elbaz M, et al. The Ras Antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One 2011;6:e18049.
16. Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, et al. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J)/dy(2J) Mouse. Ann Neurol 2012;71:699-708.
17. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med 2012;18:452-455.
18. Hinken A, Driscoll L, Godinez G, Lee K, Pannirselvan M, Hartman JJ, et al. The fast skeletal troponin activator, CK-2017357, reduces muscle fatigue in an in situ model of vascular insufficiency. In: Proceedings of the Annual Meeting of the Society for Vascular Medicine, September 30, 2010, San Francisco, CA.
19. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:430-438.
20. Meyer OA Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979;1:233-236.
21. Tankersley CG, Haenggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol 2007;102:926-932.
22. Engel BA. The histographic analysis of human muscle biopsies with regard to fibre types, Part 1 (Adult male and female). Neurology 1969;19:691-605.
23. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient Mdx mice. J Cardiovasc Pharmacol Ther 2011;16:87-95.
24. Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 2001;11:703-712.
25. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, Wewer UM, et al. Merosin-deficient congenital muscular dystrophy. J Clin Invest 1998;102:844-852.
26. Tankersley CG, Fitzgerald RS, Kleeberger SR. Differential control of ventilation among inbred strains of mice. Am J Physiol 1994;267:R1371-R1377.
27. Malik F, Russell A, Pannirselvam M, Hinken A, Thomsen K, Ardiana A, et al. The fast skeletal troponin activator, CK-2017357, increases muscle function and survival in SOD1 (G93A) mice; a model of ALS. In: Proceeding of the 64th Annual Meeting of American Academy of Neurology, New Orleans, LA, 2012.
28. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003;285:E876-E888.
29. Gentry BA, Ferreira JA, Phillips CL, Brown M. Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve 2011;43:49-57.
30. Favier FB, Benoit H, Freyssenet D. Cellular and molecular events controlling skeletal muscle mass in response to altered use. Eur J Physiol 2008;456:587-600.
31. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490:187-191.
32. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712-712.
33. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012;483:531-533.